These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1195 related items for PubMed ID: 7962337

  • 1. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [Abstract] [Full Text] [Related]

  • 2. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
    Plöckinger U, Bäder M, Hopfenmüller W, Saeger W, Quabbe HJ.
    Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
    [Abstract] [Full Text] [Related]

  • 3. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery.
    Lucas-Morante T, García-Uría J, Estrada J, Saucedo G, Cabello A, Alcañiz J, Barceló B.
    J Neurosurg; 1994 Jul; 81(1):10-4. PubMed ID: 8207509
    [Abstract] [Full Text] [Related]

  • 4. Octreotide as primary therapy for acromegaly.
    Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL.
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [Abstract] [Full Text] [Related]

  • 5. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
    Duet M, Ajzenberg C, Benelhadj S, Lajeunie E, Lormeau B, Guillausseau PJ, Rohmer V, Vilain D, Mundler O, Warnet A.
    J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
    [Abstract] [Full Text] [Related]

  • 6. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.
    Legovini P, De Menis E, Billeci D, Conti B, Zoli P, Conte N.
    J Endocrinol Invest; 1997 Aug; 20(7):424-8. PubMed ID: 9309542
    [Abstract] [Full Text] [Related]

  • 7. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
    Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, Takeshita A, Takeuchi Y, Ito J, Inoshita N.
    J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
    [Abstract] [Full Text] [Related]

  • 8. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
    Barakat S, Melmed S.
    Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
    [Abstract] [Full Text] [Related]

  • 9. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G.
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [Abstract] [Full Text] [Related]

  • 10. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide.
    Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K.
    Eur J Endocrinol; 1995 Dec; 133(6):686-90. PubMed ID: 8548053
    [Abstract] [Full Text] [Related]

  • 11. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 12. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
    Broson-Chazot F, Houzard C, Ajzenberg C, Nocaudie M, Duet M, Mundler O, Marchandise X, Epelbaum J, Gomez De Alzaga M, Schäfer J, Meyerhof W, Sassolas G, Warnet A.
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
    [Abstract] [Full Text] [Related]

  • 13. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone beta subunit response to thyrotropin-releasing hormone.
    Daneshdoost L, Gennarelli TA, Bashey HM, Savino PJ, Sergott RC, Bosley TM, Snyder PJ.
    J Clin Endocrinol Metab; 1993 Nov; 77(5):1352-5. PubMed ID: 8077332
    [Abstract] [Full Text] [Related]

  • 14. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
    Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C.
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
    [Abstract] [Full Text] [Related]

  • 15. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM.
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
    [Abstract] [Full Text] [Related]

  • 16. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
    Nobels FR, Kwekkeboom DJ, Coopmans W, Hoekstra R, De Herder WW, Bouillon R, Lamberts SW.
    J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
    [Abstract] [Full Text] [Related]

  • 17. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.
    de Bruin TW, Kwekkeboom DJ, Van't Verlaat JW, Reubi JC, Krenning EP, Lamberts SW, Croughs RJ.
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1310-7. PubMed ID: 1430093
    [Abstract] [Full Text] [Related]

  • 18. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [Abstract] [Full Text] [Related]

  • 19. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
    Teramoto A, Sanno N, Tahara S, Osamura YR.
    Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
    [Abstract] [Full Text] [Related]

  • 20. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
    Yin J, Su CB, Xu ZQ, Yang Y, Ma WB, Tao W, Yang Z, Xia XW.
    Chin Med Sci J; 2005 Mar; 20(1):23-6. PubMed ID: 15844307
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.